Fumitaka Suzuki Selected Research

Therapeutics

10/2022	Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
4/2022	Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease.
4/2021	Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
12/2020	Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma.
12/2020	Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography.
4/2020	Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C.
12/2019	Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.
1/2019	Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
1/2019	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.
10/2018	Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fumitaka Suzuki Research Topics

Disease

84	Hepatocellular Carcinoma (Hepatoma) 04/2022 - 01/2002
80	Infections 10/2022 - 01/2002
61	Chronic Hepatitis B 10/2022 - 01/2002
61	Chronic Hepatitis C 10/2022 - 01/2002
52	Fibrosis (Cirrhosis) 10/2022 - 01/2002
31	Liver Cirrhosis (Hepatic Cirrhosis) 02/2020 - 01/2002
29	Hepatitis 01/2014 - 01/2002
24	Neoplasms (Cancer) 04/2022 - 01/2003
21	Liver Diseases (Liver Disease) 10/2022 - 01/2002
20	Hepatitis B 01/2022 - 01/2002
18	Chronic Hepatitis (Chronic Active Hepatitis) 03/2014 - 01/2003
13	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2009
12	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2009
11	Anemia 01/2017 - 07/2004
11	Carcinogenesis 01/2014 - 01/2003
10	Hepatitis C 11/2015 - 09/2005
8	Liver Neoplasms (Liver Cancer) 10/2022 - 12/2010
8	Diabetes Mellitus 01/2022 - 11/2008
6	Virus Diseases (Viral Diseases) 04/2021 - 01/2004
6	Disease Progression 01/2021 - 01/2004
5	Body Weight (Weight, Body) 01/2018 - 10/2007
5	Viremia 01/2017 - 01/2007
4	Insulin Resistance 01/2022 - 06/2009
4	Hepatic Encephalopathy 12/2019 - 10/2004
4	Hypertension (High Blood Pressure) 03/2014 - 09/2009
4	Persistent Infection 10/2013 - 05/2005
3	Fatty Liver 04/2022 - 09/2009
3	Lymphoma (Lymphomas) 12/2019 - 04/2003
3	Pruritus (Itching) 09/2018 - 10/2016
3	Thrombocytopenia (Thrombopenia) 10/2017 - 05/2009
3	Fever (Fevers) 10/2016 - 03/2012
3	Headache (Headaches) 10/2016 - 04/2013
3	Liver Failure 09/2012 - 01/2004
2	Inflammation (Inflammations) 04/2022 - 01/2012

Drug/Important Bio-Agent (IBA)

80	InterferonsIBA 12/2020 - 01/2002
46	Ribavirin (Virazole)FDA LinkGeneric 02/2018 - 01/2002
42	Lamivudine (Epivir)FDA Link 05/2017 - 01/2002
31	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
30	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 02/2002
29	Hepatitis B e AntigensIBA 01/2022 - 01/2002
29	Antiviral Agents (Antivirals)IBA 04/2020 - 01/2004
20	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 01/2002
17	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2003
16	entecavir FDA Link 01/2022 - 06/2007
16	AntigensIBA 01/2022 - 01/2002
11	daclatasvirIBA 05/2018 - 04/2013
11	telaprevirIBA 02/2018 - 01/2010
11	Amino Acids FDA Link 09/2015 - 08/2008
10	Pharmaceutical PreparationsIBA 12/2018 - 11/2006
10	asunaprevirIBA 05/2018 - 04/2013
9	Transaminases (Aminotransferases)IBA 02/2015 - 08/2004
8	Proteins (Proteins, Gene)FDA Link 10/2022 - 03/2006
8	alpha-Fetoproteins (alpha-Fetoprotein)IBA 02/2020 - 01/2003
8	BilirubinIBA 10/2017 - 01/2003
8	adefovir dipivoxil (Hepsera)FDA Link 06/2014 - 01/2004
7	lenvatinibIBA 04/2022 - 01/2020
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 08/2008
7	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 01/2010
7	miriplatinIBA 06/2017 - 01/2011
6	Serum AlbuminIBA 10/2017 - 10/2007
6	lipoarabinomannan (LAM)IBA 05/2017 - 12/2007
6	adefovirIBA 06/2014 - 01/2004
6	Interferon-betaIBA 01/2011 - 01/2008
6	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2011 - 01/2006
5	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2017
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 06/2012
5	Fetal Proteins (Fetoprotein)IBA 04/2021 - 09/2013
5	glecaprevir and pibrentasvirIBA 10/2019 - 01/2018
5	AlbuminsIBA 07/2013 - 01/2009
5	Interferon-alpha (Interferon Alfa)IBA 12/2010 - 02/2002
4	SofosbuvirIBA 10/2022 - 01/2017
4	NucleotidesIBA 02/2022 - 09/2004
4	Tenofovir (Viread)FDA Link 12/2021 - 01/2014
4	Ritonavir (Norvir)FDA Link 04/2018 - 10/2015
4	Hemoglobins (Hemoglobin)IBA 10/2016 - 11/2004
4	Aspartic Acid (Aspartate)FDA Link 04/2010 - 05/2004
3	Cell-Free Nucleic AcidsIBA 04/2022 - 02/2020
3	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2017
3	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2002
3	Circular DNAIBA 01/2022 - 01/2009
3	CanagliflozinIBA 01/2022 - 05/2019
3	TransferasesIBA 04/2021 - 08/2004
3	ombitasvirIBA 04/2018 - 10/2015
3	paritaprevirIBA 04/2018 - 10/2015
3	P-300IBA 04/2018 - 01/2018
3	NucleosidesIBA 05/2017 - 06/2007
3	CreatinineIBA 03/2014 - 03/2013
3	Dihydrotachysterol (AT 10)IBA 01/2014 - 03/2009
3	PlatinumIBA 03/2013 - 04/2009
3	Tyrosine (L-Tyrosine)FDA Link 04/2010 - 05/2004
3	Methionine (L-Methionine)FDA Link 04/2010 - 05/2004
3	Alanine (L-Alanine)FDA Link 01/2010 - 08/2004
2	Peptide Hydrolases (Proteases)FDA Link 10/2022 - 04/2013

Therapy/Procedure

145	Therapeutics 10/2022 - 01/2002
15	Radiofrequency Ablation 02/2019 - 01/2002
6	Retreatment 03/2019 - 04/2003
6	Drug Tapering 10/2013 - 07/2004
4	Aftercare (After-Treatment) 02/2021 - 12/2006
4	Hepatectomy 10/2020 - 07/2005
4	Drug Therapy (Chemotherapy) 09/2013 - 11/2011